MetaVia's experimental obesity drug DA-1726 — a once-weekly injection targeting both GLP-1 and glucagon receptors — produced over 9% body weight loss in just 54 days at its highest tested dose. Presented at the American Diabetes Association 2026 Scientific Sessions, Phase 1 data showed waist circumference dropped nearly 10 cm and BMI fell 3.4 points with no serious adverse events or dropouts. A second drug, vanoglipel, showed promising liver-protective and weight-loss effects in preclinical models of fatty liver disease and type 2 diabetes. Both drugs represent a next wave of obesity therapeutics building on the GLP-1 drug revolution.
